Diabetes & Endocrinologycase reportmedullary thyroid carcinoma
Exceptional and Durable Response to Selpercatinib in a Patient with Apparently RET-Negative, HRAS-, and NF1-Mutated Metastatic Medullary Thyroid Carcinoma
By MedXY|Oct 5, 2026
A 50-year-old woman with metastatic medullary thyroid carcinoma (MTC) lacking RET alterations exhibited a remarkable sustained response to selpercatinib, suggesting potential efficacy beyond RET-mutated cases.
